Enhancing the responsiveness of gliomas to immunotherapy by pharmacological inhibition of Chek2: Setting the stage for a clinical trial

rismita Dmello, PhD is an aspiring translational scientist with innovative ideas and relevant questions. Her commitment to scientific pursuit and research is recognized by her first author publications and many other co-authored publications. Dr. Dmello is planning to develop top quality basic and translational research in an academic setting as an independent investigator, growing in collaborations and utilizing innovative ideas and cutting edge approaches to fight glioblastoma (GBM). She plans to maximize the benefits from immunotherapy in Glioblastoma. In Dr. Sonabend’s laboratory, she has co-authored one peered review publication and the other work is in review in Clinical Cancer Research. Focus of her work for past one year has been to identify predictive biomarkers for the response to paclitaxel and to study tumor intrinsic factors that limit recognition by CD8 T cells and hence response to immunotherapy in GBM. Dr. Dmello relies on high-throughput CRISPR KO technology to investigate these questions both in vitro as well as in intracranial glioma models.